Yes and Elan lost 10B on the failure of the phase 2. I get the feeling Dimebon soured the water somewhat for small development AD companies. Having JNJ and PFE on board didn't hurt Elan. I guess Selkoe was just a very good salesman as well as a brilliant scientist. Everything I have seen so far, including the HD results and even mouse tests indicate PBT2 will be at its most effective in very early stage. Being able to provide a measurable cognition improvement even before plaques appear will make it sought after. I think you will be OK, my family has cardomyopathy running through the past generations and there is not too much for that yet.
Market Data 
Markets 
AI
